Growth Metrics

Elutia (ELUT) Preferred Stock Liabilities (2019 - 2020)

Elutia recorded quarterly Preferred Stock Liabilities of $56.6 million in Q3 2020, up 26.05% quarter-over-quarter from $44.9 million in Q2 2020, and up 36.66% year-over-year from $41.4 million in Q4 2019.

Elutia's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $56.6 million for Q3 2020.

  • In Q3 2020, Preferred Stock Liabilities rose 36.66% year-over-year to $56.6 million; the TTM figure through Sep 2020 stood at $56.6 million (up 36.66% YoY), while the FY2019 annual figure was $44.4 million, changed N/A from the prior year.
  • Preferred Stock Liabilities came in at $56.6 million for Q3 2020 at Elutia, up from $44.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $56.6 million in Q3 2020 to a low of $41.4 million in Q3 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Elutia 45.79 Mn 17.31 Mn 1.80 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2020 56.59 Mn
Jun 30, 2020 44.90 Mn
Mar 31, 2020 44.90 Mn
Dec 31, 2019 44.45 Mn
Sep 30, 2019 41.41 Mn